The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients.
暂无分享,去创建一个
G. Raskob | M. Prins | P. Prandoni | S. Middeldorp | H. ten Cate | P. Mismetti | J. Weitz | D. Kubitza | A. Lensing | J. Beyer-Westendorf | M. Gebel | T. Brighton